ACRS Company Profile and Key Details

Q: Who are the executives of ACRS?

Mr. Matthew Rothman J.D.Gen. Counsel & Corporation Sec.Dr. Gail Cawkwell M.D., Ph.D.Chief Medical OfficerMr. Frank RuffoCo-Founder, Chief Financial Officer , Sec. & TreasurerMr. Robert A. Doody Jr.Vice President of Investor RelationsDr. Paul S. Changelian Ph.D.Senior Vice President of BiologyDr. Neal S. Walker D.O.Co-Founder & ChairmanDr. Jon Jacobsen Ph.D.Senior Vice President of ChemistryDr. Douglas J. Manion Frcp(C), M.D.Chief Executive Officer, Pres & DirectorDr. Joseph MonahanChief Scientific OfficerMr. James LoeropChief Bus. OfficerDr. Ian Anderson Ph.D.Executive Vice President of Translational R&DMr. Gary A. DeCrescenzoSenior Vice President of Pharmaceutical R&DMr. Kevin BalthaserChief Financial OfficerDr. Joseph Monahan Ph.D.Chief Scientific Officer

NASDAQ : ACRS

Aclaris Therapeutics

$2.64

-0.04-1.49%

Open: 4:00 PM

72.81

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Aclaris Therapeutics, Inc. (ACRS) stock declined over -1.49%, trading at $2.64 on NASDAQ, down from the previous close of $2.68. The stock opened at $2.69, fluctuating between $2.63 and $2.74 in the recent session.

Stock Snapshot

2.68

Prev. Close

286.03M

Market Cap

2.63

Day Low

-1.67

P/E Ratio

-1.58

EPS (TTM)

-1.12

Cash Flow per Share

2.69

Open

108.35M

Number of Shares

2.735

Day High

85.19%

Free Float in %

2.22

Book Value

476.35K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 09, 2026	2.68	2.74	2.63	2.64	494.7K
Jan 08, 2026	2.65	2.69	2.59	2.68	762.02K
Jan 07, 2026	2.65	2.75	2.60	2.68	919.35K
Jan 06, 2026	2.76	2.79	2.49	2.65	2.47M
Jan 05, 2026	2.90	2.90	2.58	2.65	1.02M
Jan 02, 2026	3.01	3.04	2.82	2.88	698.61K
Dec 31, 2025	2.90	3.03	2.90	3.01	463.09K
Dec 30, 2025	3.02	3.02	2.88	2.90	374.13K
Dec 29, 2025	3.02	3.05	2.98	3.01	429.54K
Dec 26, 2025	3.04	3.05	2.99	3.03	498.21K
Dec 24, 2025	2.91	3.09	2.91	3.04	440.37K
Dec 23, 2025	3.05	3.06	2.78	2.90	1.72M
Dec 22, 2025	3.09	3.14	3.03	3.07	550.4K
Dec 19, 2025	3.09	3.23	3.05	3.14	2.46M
Dec 17, 2025	3.26	3.26	3.03	3.03	1.04M
Dec 16, 2025	3.18	3.31	3.11	3.21	1.09M
Dec 15, 2025	3.25	3.39	3.16	3.17	1.53M
Dec 12, 2025	3.41	3.41	3.25	3.25	958.86K
Dec 11, 2025	3.29	3.48	3.23	3.37	1.95M
Dec 10, 2025	3.21	3.29	3.12	3.27	1.51M

Contact Details

Wayne, PA 19087

United States

https://www.aclaristx.com 484 324 7933

About Company

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Stock Peers

IDXX

0.96+0.13%

IDEXX Laboratories, Inc.$713.35 MEDP

-5.02-0.84%

Medpace Holdings, Inc.$595.00 NTRA

-5.25-2.19%

Natera, Inc.$234.31 ICLR

-6.84-3.63%

ICON Public Limited Company$181.38 ILMN

-4.76-3.26%

Illumina, Inc.$141.07 GH

1.43+1.32%

Guardant Health, Inc.$110.17 EXAS

0.33+0.32%

Exact Sciences Corporation$102.11 GRAL

2.06+2.10%

GRAIL, Inc.$100.10 BLLN

-1.65-1.88%

BillionToOne, Inc.$85.94 RDNT

-0.18-0.23%

RadNet, Inc.$78.20

Frequently Asked Questions

What is the current Aclaris Therapeutics, Inc. (ACRS) stock price?

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) stock price is $2.64 in the last trading session. During the trading session, ACRS stock reached the peak price of $2.74 while $2.63 was the lowest point it dropped to. The percentage change in ACRS stock occurred in the recent session was -1.49% while the dollar amount for the price change in ACRS stock was - $0.04.

ACRS's industry and sector of operation?

The NASDAQ listed ACRS is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Aclaris Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ACRS?

Mr. Matthew Rothman J.D.
Gen. Counsel & Corporation Sec.
Dr. Gail Cawkwell M.D., Ph.D.
Chief Medical Officer
Mr. Frank Ruffo
Co-Founder, Chief Financial Officer , Sec. & Treasurer
Mr. Robert A. Doody Jr.
Vice President of Investor Relations
Dr. Paul S. Changelian Ph.D.
Senior Vice President of Biology
Dr. Neal S. Walker D.O.
Co-Founder & Chairman
Dr. Jon Jacobsen Ph.D.
Senior Vice President of Chemistry
Dr. Douglas J. Manion Frcp(C), M.D.
Chief Executive Officer, Pres & Director
Dr. Joseph Monahan
Chief Scientific Officer
Mr. James Loerop
Chief Bus. Officer
Dr. Ian Anderson Ph.D.
Executive Vice President of Translational R&D
Mr. Gary A. DeCrescenzo
Senior Vice President of Pharmaceutical R&D
Mr. Kevin Balthaser
Chief Financial Officer
Dr. Joseph Monahan Ph.D.
Chief Scientific Officer

How ACRS did perform over past 52-week?

ACRS's closing price is 151.43% higher than its 52-week low of $1.05 where as its distance from 52-week high of $3.48 is -24.03%.

How many employees does ACRS have?

Number of ACRS employees currently stands at 61.

Link for ACRS official website?

Official Website of ACRS is: https://www.aclaristx.com

How do I contact ACRS?

ACRS could be contacted at phone 484 324 7933 and can also be accessed through its website. ACRS operates from 640 Lee Road, Wayne, PA 19087, United States.

How many shares of ACRS are traded daily?

ACRS stock volume for the day was 476.35K shares. The average number of ACRS shares traded daily for last 3 months was 1.32M.

What is the market cap of ACRS currently?

The market value of ACRS currently stands at $286.03M with its latest stock price at $2.64 and 108.35M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	61
Beta	0.43
Sales or Revenue	$31.25M
5Y Sales Change%	0.46%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

Employees	61
Beta	0.43
Sales or Revenue	$31.25M
5Y Sales Change%	0.46%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

ACRS Company Profile and Key Details

Aclaris Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Price Forecast & Outlook

Key Takeaways